Navigation Links
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
Date:6/7/2009

LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly reduced blood glucose levels and provided weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

In the study, dose-dependent reductions in A1C - a measure of how well blood sugar is being controlled over time - with albiglutide 30 mg weekly, 50 mg biweekly, and 100 mg monthly were 0.9%, 0.8% and 0.9% respectively (p<0.05). The A1C reduction by placebo was 0.2% and by open-label exenatide was 0.5%. Weight loss (0.9 to 1.8 kg) was observed across all doses. The most frequently reported adverse events included nausea, vomiting and headache. At the 30 mg weekly dose, fewer than 10% of patients experienced nausea and vomiting, which subsided after week eight. Albiglutide was not shown to increase the risk of abnormally low blood sugar, known as hypoglycemia.

"Despite a range of available diabetes therapies, over half of patients with type 2 diabetes are unable to achieve the ADA target blood sugar goal," said the study's lead investigator, Julio Rosenstock, MD of the Dallas Diabetes and Endocrine Center at Medical City and clinical professor of medicine, University of Texas Southwestern Medical School. "While these results need to be confirmed in ongoing studies, the findings with albiglutide are important since weight gain and fear of increased blood sugar levels can be major barriers to diabetes management."

Study design

The primary objective of the study was to evaluate the dose response of albiglutide for safety and efficacy. The primary efficacy endpoint was cha
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... WOONSOCKET, R.I., Feb. 14, 2012  CVS Caremark (NYSE: ... impact study of CVS Caremark,s contribution to the ... company,s national headquarters is located.  According to the ... for CVS Caremark, the company,s Rhode Island operations ...
... Feb. 14, 2012 Watson Pharmaceuticals, Inc. (NYSE: ... $1.5 billion for the fourth quarter ended December 31, 2011, ... a non-GAAP basis, net income for the fourth quarter 2011 ... 93 percent, compared to $116.5 million or $0.93 per share ...
Cached Medicine Technology:Report: CVS Caremark Contributes Billions to Rhode Island Economy 2Report: CVS Caremark Contributes Billions to Rhode Island Economy 3Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 2Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 3Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 4Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 5Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 6Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 7Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 8Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 9Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 10Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 11Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 12Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 13Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion; 14
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Sayre Area School District in Bradford County today became ... H1N1 influenza vaccine to its student population, the Department ... reminded all parents that immunizations play a significant role ... disproportionately affecting school-aged children, with almost two-thirds of all ...
... into diseases and treatments, experts say , FRIDAY, Oct. ... detailed map of the human epigenome, gaining greater understanding ... past, we,ve been limited to viewing small snippets of ... Genomic Analysis Laboratory at the Salk Institute for Biological ...
... RATON, Fla., Oct. 16 Although stem cells sounds ... for quite some time. In today,s advanced medical ... orthopedic conditions including osteoarthritis of the hip knee and ... rotator cuff tears, and various back conditions including ...
... physicians will be using electronic prescribing and other health ... million federal grant secured by U.S. Senator Patrick Leahy. ... Technology Leaders, Inc. (VITL), will provide incentives to physicians ... In June, Vermont was cited by Surescripts as the ...
... DALLAS, Oct. 16 John Killian, Chairman of Parent ... the United States focused on finding a cure for Duchenne ... that the 5th Annual Sam,s Family Fun Day ... 10am to 2pm on Flagpole Hill at White Rock Lake. ...
... The Avon Foundation for Women is marking Breast ... celebrations, and tributes. Throughout October, the Foundation will call ... save lives, and raise millions of dollars for the ... the sale of fundraising products, Avon Walks for Breast ...
Cached Medicine News:Health News:Pennsylvania Department of Health Announces First School to Begin Administering H1N1 Vaccine to Students 2Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 2Health News:Stem Cell and PRP Therapy for Orthopedic Conditions 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 2Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 3Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 4Health News:Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont 5Health News:Sam's Day Celebrates 5 Year Anniversary; Local Family Event Will Benefit Largest U.S. Non-Profit Fighting Duchenne Muscular Dystrophy 2Health News:Sam's Day Celebrates 5 Year Anniversary; Local Family Event Will Benefit Largest U.S. Non-Profit Fighting Duchenne Muscular Dystrophy 3Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 2Health News:Photos: Avon Foundation for Women Celebrates Breast Cancer Awareness Month 3
... CardioDirect12-S is the stress testing system from ... turn-key system including treadmill or bicycle ergometer, ... BP option. It uses the same CardioDirect ... resting ECG. ,The system is ...
... monitor, store and measure data during the performance ... organize the amount of information detected during the ... and printout of an extremely flexible final report. ... small portable ECG recorder (ECT 12 no ...
... Marco's CP-690E Automatic Chart Projector makes refracting ... you program up to 33 charts in any ... examination in a darkened room simply by pressing ... to the next chart. In addition, the CP-690E's ...
... Ultimate in Stability. ... stabilizer features superior arm ... in the clamp/turret mechanism. ... features the ultimate flexibility ...
Medicine Products: